The scenario of the Pediatric Vaccines segment : Ken Research

India has emerged as the leading vaccine producer in the world, in terms of doses of vaccines produced, and has about ~ major vaccine manufacturing facilities across the country. Vaccines manufactured in these facilities are offered in both national and international market (over 150 countries). With over ~ million births every year, the domestic market for vaccines in India is huge. The country has been self sufficient in meeting the domestic needs, with private sector responsible for providing a large part of the supply needs. However, India lacks in coverage rate of basic vaccines.
The Indian domestic market for Universal Immunization Programme (UIP) alone is over ~ million doses. The R&D cost of UIP vaccines is minimal; however, the non-UIP vaccines involve technology licensing, R&D, infrastructure and operational costs. In addition, stringent regulatory requirements for the licensing of newer vaccines, add up to the cost.

More than ~% of all measles vaccines used globally are produced in India. Moreover, Indian firms are big suppliers to the UN agencies, accounting in between ~% and ~% of the vaccines purchased by organization every year. India has emerged as a major vaccine producer in recent times by focusing on geographical regions where vaccines are not funded by the UN or charitable organizations and strategic ties with UN and government agencies to supply vaccines at affordable prices.
The Indian pediatric market for vaccines has grown at a remarkable CAGR of ~% during the period FY’2011-FY’2016.
The growth was attributed to some crucial vaccines (polio, hepatitis B, MMR and BCG) manufactured by Indian companies constantly featured in WHO’s prequalified list coupled with the fact that Indian companies (Serum Institute of India, Bharat Biotech, Panacea Biotec) acted as major suppliers of vaccines to WHO, UNICEF, PATH and other UN agencies. The market for pediatric vaccines grew from INR ~ billion in FY’2011 to INR ~ billion in FY’2016.
Monovalent vaccines are meant to immunize against a single antigen or a single microorganism. A fact that large chunk of vaccines administered under the national immunization programme in the country are of the monovalent form, is the major factor which has resulted in high revenue contribution from the segment. This includes monovalent oral polio vaccine, BCG, measles, Hepatitis B and Hib. Some other commonly used monovalent vaccines include rotavirus vaccine and TT.
Topics Covered in the Report

• Vaccines Market Growth India,
• Drug Pipeline Pediatric ,
• Pediatric tuberculosis drug Market,
• Number of Pediatrician  Statistics,
• Drug Information Dosage Side Effects,
• Pediatric Vaccine Serum Institute of India,
• New Drug Launches India Pharma Sector,

For more information about the publication, refer to below link:
https://www.kenresearch.com/healthcare/pharmaceuticals/india-pediatric-drug-vaccine-market/81319-91.html
Related Reports:
Global Glaucoma Treatment Drugs Market Forecast to 2020 - New Product Launches Expected to Boost Market
US Aesthetic Lasers and Energy Devices Market Outlook to 2020 - Aging Population and High Prevalence Rate of Obesity to Foster Future Growth
Qatar Wellness Market Outlook to 2020 - Rising Awareness about health & Fitness and Prevalence in Lifestyle Diseases will drive the Market
Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications
Ankur@kenresearch.com
+91-9015378249

Rising prevalence of chronic diseases & Inclusion of Several New Vaccines in National Immunization Programme to shape India Pediatric Drugs and Vaccines Market: Ken Research

“Launch of Anti TB drugs, introduction of IPV and several other vaccines in the national immunization programme to drive the India Pediatric Drugs and Vaccines Market”

India pediatric drugs and vaccine market has witnessed tremendous growth in the last five years largely due to high number of annual births recorded at around 25 million, launch of generic formulations of several pediatric drugs including flavored TB drugs, inclusion of several vaccines in the national immunization schedule of the country and inclining coverage of children vaccination under national immunization schedule.
Although a vast majority of the drugs sold in the country has been directed for the treatment of diseases as compared to management of the same. With rising prevalence of chronic diseases in the pediatric population of the country including diabetes and asthma, the market for drugs meant for management of diseases is deemed to incline at a faster pace in the near future.

Currently, procurement of pediatric drugs is almost entirely done through offline medium from hospital pharmacies, retail pharmacies, doctors or institutional health centers. Since the requirement of drugs is usually on an urgent basis, parents don’t prefer placing an order online and receive it a later date. However, online pharmacies have expanded at a steep pace in the last few years. Several players including the likes of Netmeds.com, 1mg, buydrug.in, Zigy, apollopharmacy.in and medidart.com have provided the much needed momentum to online retailing space. In the mid-long term, online sale of drugs is expected to witness healthy growth.
A large chunk of vaccines administered under the national immunization programme in the country are of the monovalent form. This includes monovalent oral polio vaccine, BCG, measles, Hepatitis B and Hib. Some other commonly used monovalent vaccines include rotavirus vaccine and TT. Monovalent vaccines therefore comprised for the maximum market share as of FY’2016. However, with the expected inclusion of pentavalent in the immunization programme and launch of several multivalent vaccines in the country, the market share of multivalent vaccines is expected to incline.
The market for pediatrics vaccine in India has grown at a tremendous pace in the last five years. With the introduction of new vaccines in the national immunization programme, the market is expected to perform even better in the next five years. Indian government, as per the recommendation of WHO, has included Injectable Polio Vaccine (IPV) in its Universal Immunization Program. Further, the usage of pentavalent vaccine has been expanded to all the states and union territories. India has an ambition to eliminate measles, introduce rubella (as part of Measles Rubella vaccine), rotavirus and pneumococcal vaccines in 2017 and potentially Human Papilloma Virus (HPV) vaccine and Japanese Encephalitis vaccine at a later time, impacting the total India pediatric drugs and vaccines market in a positive manner.
With expected launch of rotavirus vaccine by Serum Institute of India in FY’2017 and quadrivalent influenza vaccine by Sanofi in FY’2018 amongst other vaccines, the pediatrics vaccine market is expected to grow at a high pace. .
The report titled “India Pediatric Drugs and Vaccines Market – Rise in prevalence of chronic diseases and inclusion of several new vaccines in national immunization programme to Shape Future Growth” provides detailed overview on the pediatric drugs and vaccines market in India. This report helps readers to identify the ongoing trends in the industry and anticipated growth in future depending upon changing industry dynamics in coming years. The report is useful for investors, pharmaceutical companies, contract manufacturers, startups, and other stakeholders to align their market centric strategies according to ongoing and expected trends in the future.
For more information about the publication, refer to the below link:
https://www.kenresearch.com/healthcare/pharmaceuticals/india-pediatric-drug-vaccine-market/81319-91.html
Related Reports:
Global Glaucoma Treatment Drugs Market Forecast to 2020 - New Product Launches Expected to Boost Market
US Aesthetic Lasers and Energy Devices Market Outlook to 2020 - Aging Population and High Prevalence Rate of Obesity to Foster Future Growth
Qatar Wellness Market Outlook to 2020 - Rising Awareness about health & Fitness and Prevalence in Lifestyle Diseases will drive the Market
Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications
Ankur@kenresearch.com
+91-9015378249